Prof. Dr. Daley GQ and co-workers from Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Children’s Hospital Boston (Harvard Medical School Teaching Hospital), Boston, Massachusetts, USA have reported recently in the prestigious journal Genes & Development. (April 14, 2014) that Lin28 sustains early renal progenitors and induces Wilms tumor.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Treating cancer with a diabetic drug: Metformin , the widely used drug in the treatment of TIIDM, inhibits expansion of nephrogenic progenitors and wilms tumor formation by inducing its target gene. This data may suggest that Metformin and its analogs may serve as one of the promising therapeutic candidates in the treatment of renal cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Treating human cancer with a diabetic drug: Metformin, the widely used drug in the treatment of TIIDM, inhibits expansion of nephrogenic progenitors and wilms tumor formation by inducing its target gene, 2/May/2014, 8.19 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
